MX383599B - Inhibidores de la dipeptidil peptidasa-4 para su uso en el tratamiento topico ocular de enfermedades neurodegenerativas de la retina, en particular en estadios tempranos de retinopatia diabetica y otras enfermedades retinianas en las que la neurodegeneracion desempe?a un papel esencial - Google Patents
Inhibidores de la dipeptidil peptidasa-4 para su uso en el tratamiento topico ocular de enfermedades neurodegenerativas de la retina, en particular en estadios tempranos de retinopatia diabetica y otras enfermedades retinianas en las que la neurodegeneracion desempe?a un papel esencialInfo
- Publication number
- MX383599B MX383599B MX2018013022A MX2018013022A MX383599B MX 383599 B MX383599 B MX 383599B MX 2018013022 A MX2018013022 A MX 2018013022A MX 2018013022 A MX2018013022 A MX 2018013022A MX 383599 B MX383599 B MX 383599B
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitors
- neurodegenerative diseases
- dipeptidyl peptidase
- eye treatment
- topical eye
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16382190 | 2016-04-29 | ||
| PCT/EP2017/060234 WO2017186934A1 (en) | 2016-04-29 | 2017-04-28 | Dipeptidyl peptidase-4 inhibitors for topical eye treatment of retinal neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX383599B true MX383599B (es) | 2025-03-14 |
Family
ID=55953092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018013022A MX383599B (es) | 2016-04-29 | 2017-04-28 | Inhibidores de la dipeptidil peptidasa-4 para su uso en el tratamiento topico ocular de enfermedades neurodegenerativas de la retina, en particular en estadios tempranos de retinopatia diabetica y otras enfermedades retinianas en las que la neurodegeneracion desempe?a un papel esencial |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11013738B2 (https=) |
| EP (1) | EP3448388B1 (https=) |
| JP (1) | JP7068706B2 (https=) |
| KR (1) | KR102411574B1 (https=) |
| CN (1) | CN109152776B (https=) |
| AU (1) | AU2017256803B2 (https=) |
| BR (1) | BR112018072127A2 (https=) |
| CA (1) | CA3022152C (https=) |
| DK (1) | DK3448388T3 (https=) |
| ES (1) | ES2863701T3 (https=) |
| IL (1) | IL262526B (https=) |
| MX (1) | MX383599B (https=) |
| RU (1) | RU2744878C2 (https=) |
| WO (1) | WO2017186934A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7068706B2 (ja) * | 2016-04-29 | 2022-05-17 | フンダシオ オスピタル ウニベルシタリ バル デブロン－インスティテュート デ レセルカ | 網膜神経変性疾患の眼局所治療のためのジペプチジルペプチダーゼ－４阻害剤 |
| RU2727898C1 (ru) * | 2020-02-25 | 2020-07-24 | Общество с ограниченной ответственностью «Необиотек» | Фармацевтическая композиция на основе действующего вещества, ингибитора дипептидилпептидазы-4, для предупреждения развития и лечения сахарного диабета 2 типа |
| CN111166870A (zh) * | 2020-03-18 | 2020-05-19 | 复旦大学附属眼耳鼻喉科医院 | 艾塞那肽在制备滴眼治疗眼部缺血疾病、改善眼部血液循环的药物中的应用 |
| GB202014740D0 (en) * | 2020-09-18 | 2020-11-04 | Invex Therapeutics Ltd | Method of reducing intraocular pressure |
| WO2026078034A1 (en) | 2024-10-09 | 2026-04-16 | Fundació Hospital Universitari Vall D'hebron - Institut De Recerca | Sitagliptin for use in retinal diseases with neovascularization |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19616486C5 (de) * | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| RU2008116578A (ru) * | 2005-09-30 | 2009-11-10 | Новартис АГ (CH) | Применение ингибиторов dpp-iv для лечения аутоиммунных заболеваний и отторжения трансплантата |
| US7560597B2 (en) * | 2007-03-08 | 2009-07-14 | The University Court Of The University Of Aberdeen | 2′,4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds and their use as therapeutic agents |
| WO2009084024A2 (en) * | 2007-11-02 | 2009-07-09 | Glenmark Generics Limited | A process for the preparation of r-sit agliptin and its pharmaceutically acceptable salts thereof |
| US20100330177A1 (en) * | 2008-02-05 | 2010-12-30 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor |
| EP2251028A1 (en) * | 2009-05-12 | 2010-11-17 | Biocompatibles Uk Ltd. | Treatment of eye diseases using encapsulated cells encoding and secreting an anti-angiogenic factor and/or a neuroprotective factor |
| CN101921270A (zh) * | 2009-06-16 | 2010-12-22 | 海南德泽药物研究有限公司 | 一种芒果苷小檗碱盐及其制备方法与用途 |
| TWI469785B (zh) * | 2012-04-25 | 2015-01-21 | Inovobiologic Inc | 用於治療代謝性疾病之膳食纖維組成物 |
| JP6368722B2 (ja) * | 2013-03-01 | 2018-08-01 | フンダシオ オスピタル ウニベルシタリ バル デブロン−インスティテュート デ レセルカ | 網膜神経変性疾患の、特に、初期の糖尿病性網膜症及び神経変性が本質的な役割を果たす他の網膜疾患における局所治療における使用のためのペプチド |
| CA2914791A1 (en) * | 2013-06-14 | 2014-12-18 | Boehringer Ingelheim International Gmbh | Dpp-4 inhibitors for treating diabetes and its complications |
| JP7068706B2 (ja) * | 2016-04-29 | 2022-05-17 | フンダシオ オスピタル ウニベルシタリ バル デブロン－インスティテュート デ レセルカ | 網膜神経変性疾患の眼局所治療のためのジペプチジルペプチダーゼ－４阻害剤 |
-
2017
- 2017-04-28 JP JP2018555725A patent/JP7068706B2/ja active Active
- 2017-04-28 US US16/095,621 patent/US11013738B2/en active Active
- 2017-04-28 KR KR1020187033209A patent/KR102411574B1/ko active Active
- 2017-04-28 AU AU2017256803A patent/AU2017256803B2/en active Active
- 2017-04-28 CA CA3022152A patent/CA3022152C/en active Active
- 2017-04-28 ES ES17722716T patent/ES2863701T3/es active Active
- 2017-04-28 WO PCT/EP2017/060234 patent/WO2017186934A1/en not_active Ceased
- 2017-04-28 EP EP17722716.2A patent/EP3448388B1/en active Active
- 2017-04-28 CN CN201780030017.3A patent/CN109152776B/zh active Active
- 2017-04-28 BR BR112018072127-1A patent/BR112018072127A2/pt not_active Application Discontinuation
- 2017-04-28 DK DK17722716.2T patent/DK3448388T3/da active
- 2017-04-28 RU RU2018140127A patent/RU2744878C2/ru active
- 2017-04-28 MX MX2018013022A patent/MX383599B/es unknown
-
2018
- 2018-10-22 IL IL262526A patent/IL262526B/en unknown
-
2021
- 2021-04-29 US US17/244,889 patent/US11918577B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN109152776A (zh) | 2019-01-04 |
| JP7068706B2 (ja) | 2022-05-17 |
| RU2018140127A3 (https=) | 2020-07-02 |
| WO2017186934A1 (en) | 2017-11-02 |
| US11918577B2 (en) | 2024-03-05 |
| EP3448388B1 (en) | 2020-11-18 |
| BR112018072127A2 (pt) | 2019-03-19 |
| IL262526B (en) | 2022-05-01 |
| KR102411574B1 (ko) | 2022-06-21 |
| CA3022152A1 (en) | 2017-11-02 |
| EP3448388A1 (en) | 2019-03-06 |
| AU2017256803B2 (en) | 2022-12-01 |
| RU2018140127A (ru) | 2020-05-29 |
| US11013738B2 (en) | 2021-05-25 |
| JP2019519479A (ja) | 2019-07-11 |
| CA3022152C (en) | 2024-10-29 |
| ES2863701T3 (es) | 2021-10-11 |
| KR20190003575A (ko) | 2019-01-09 |
| DK3448388T3 (da) | 2021-02-08 |
| US20210315890A1 (en) | 2021-10-14 |
| CN109152776B (zh) | 2022-04-29 |
| IL262526A (en) | 2018-12-31 |
| US20190134030A1 (en) | 2019-05-09 |
| AU2017256803A1 (en) | 2018-12-06 |
| RU2744878C2 (ru) | 2021-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024004439A (es) | Agentes terapeuticos para enfermedades neurodegenerativas | |
| EA201892431A1 (ru) | Олигонуклеотиды для лечения заболевания глаз | |
| PH12017500621A1 (en) | Triazolopyrazinones as pde1 inhibitors | |
| PH12017501990A1 (en) | Imidazopyrazinones as pde1 inhibitors | |
| MX2016000364A (es) | Metodos para tratar o prevenir afecciones oftalmologicas. | |
| MX383599B (es) | Inhibidores de la dipeptidil peptidasa-4 para su uso en el tratamiento topico ocular de enfermedades neurodegenerativas de la retina, en particular en estadios tempranos de retinopatia diabetica y otras enfermedades retinianas en las que la neurodegeneracion desempe?a un papel esencial | |
| MX2017006437A (es) | Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor. | |
| PH12018502161A1 (en) | Methods of treatment for cholestatic and fibrotic diseases | |
| WO2018208793A8 (en) | S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY | |
| PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| PH12016501173A1 (en) | Quinazolin-thf-amines as pde1 inhibitors | |
| PH12016501938A1 (en) | Halogenated quinazolin-thf-amines as pde1 inhibitors | |
| WO2017143115A3 (en) | Enhancing the therapeutic activity of an immune checkpoint inhibitor | |
| EP4342544A3 (en) | Enhancing the therapeutic activity of an immune checkpoint inhibitor | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| PH12016501495A1 (en) | Hexahydrofuropyrroles as pde1 inhibitors | |
| MX345534B (es) | Compuestos y combinaciones farmaceuticas para el tratamiento de enfermedades cerebrales isquemicas y neurodegenerativas. | |
| ZA201906153B (en) | Pharmaceutical compositions for combination therapy | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| MX2021004860A (es) | Piridazinas novedosas. | |
| HK1248119A1 (zh) | 有机氧化砷化合物和mtor抑制剂的药物组合 | |
| MX2018015240A (es) | Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica. | |
| EA201991866A1 (ru) | Комбинированная терапия |